BMJ 2000;321:267-272 ( 29 July )

Papers

Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review

Lionel Dumont, staff anaesthesiologist, ^a Chahé Mardirosoff, staff anaesthesiologist, ^b Martin R Tramèr, staff anaesthesiologist. ^a

^a Division of Anaesthesiology, Department APSIC, University of Geneva Hospitals, CH-1211 Geneva 14, Switzerland, ^b Département d'Anesthésie-Réanimation, Hôpital Sud-Léman-Valserine, 74164 Saint-Julien en Genevois, France

Correspondence to: L Dumont lionel.dumont{at}hcuge.ch

Objective: To quantify efficacy and harm of pharmacological prevention of acute mountain sickness.
Data sources: Systematic search (Medline, Embase, Cochrane Library, internet, bibliographies, authors) in any language, up to October 1999.
Study selection: Randomised placebo controlled trials.
Data extraction: Dichotomous data on efficacy and harm from 33 trials (523 subjects received 13 different interventions, 519 a placebo).
Data synthesis: At above 4000 m the mean incidence of acute mountain sickness with placebo was 67% (range 25% to 100%); incidence depended on the rate of ascent, but not on the altitude or the mode of ascent. Across all ascent rates, dexamethasone 8-16 mg prevented acute mountain sickness (relative risk 2.50 (95% confidence interval 1.71 to 3.66); number needed to treat (NNT) 2.8 (2.0 to 4.6)), without evidence of dose responsiveness. Acetazolamide 750 mg was also efficacious (2.18 (1.52 to 3.15); NNT 2.9 (2.0 to 5.2)), but 500 mg was not. In two trials, adverse reaction (including depression) occurred after dexamethasone was stopped abruptly (4.45 (1.08 to 18); NNT 3.7 (2.5 to 6.9)). With acetazolamide, paraesthesia (4.02 (1.71 to 9.43); NNT 3.0 (2.0 to 6.0)) and polyuria (4.24 (1.92 to 9.37); NNT 3.6 (2.5 to 6.2)) were reported. Data were sparse on nifedipine, frusemide (furosemide), dihydroxyaluminium-sodium, spironolactone, phenytoin, codeine, phenformin, antidiuretic hormone, and ginkgo biloba.
Conclusions: At above 4000 m, with a high ascent rate, fewer than three subjects need to be treated with prophylactic dexamethasone 8-16 mg or acetazolamide 750 mg for one subject not to experience acute mountain sickness who would have done so had they all received a placebo. Acetazolamide 500 mg does not work.

---

© BMJ 2000
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Effect of altitude on physiological performance: a statistical analysis using results of international football games

Patrick E McSharry
BMJ 2007 335: 1278-1281. [Abstract] [Full Text] [PDF]

Pharmacological prevention of acute mountain sickness

Peter Hackett, Peter Bärtsch, Michael Schneider, L Dumont, M R Tramèr, and C Mardirosoff
BMJ 2001 322: 48. [Extract] [Full Text]

Prevention of acute mountain sickness depends on ascent rate and drug dose
BMJ 2000 321: 0. [Full Text]

This article has been cited by other articles:

• Jafarian, S, Abolfazli, R, Gorouhi, F, Rezaie, S, Lotfi, J (2008). Gabapentin for prevention of hypobaric hypoxia-induced headache: Randomized double-blind clinical trial. J. Neurol. Neurosurg. Psychiatry 79: 321-323 [Abstract] [Full text]  
• McSharry, P. E (2007). Effect of altitude on physiological performance: a statistical analysis using results of international football games. BMJ 335: 1278-1281 [Abstract] [Full text]  
• Spooner, L. M., Olin, J. L., Debellis, R. J. (2007). Pharmacotherapy of High-Altitude Illness. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 129-141 [Abstract]  
• Brubaker, P. L. (2005). Adventure Travel and Type 1 Diabetes: The complicating effects of high altitude. Diabetes Care 28: 2563-2572 [Full text]  
• West, J. B. (2004). The Physiologic Basis of High-Altitude Diseases. ANN INTERN MED 141: 789-800 [Full text]  
• Gertsch, J. H, Basnyat, B., Johnson, E W., Onopa, J., Holck, P. S (2004). Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 328: 797- [Abstract] [Full text]  
• Wong, S. H., Turner, N., Birchall, D., Walls, T. J., English, P., Schmid, M. L. (2004). Reversible abnormalities of DWI in high-altitude cerebral edema. Neurology 62: 335-336 [Full text]  
• Barry, P W, Pollard, A J (2003). Altitude illness. BMJ 326: 915-919 [Full text]  
• Garske, L. A., Brown, M. G., Morrison, S. C. (2003). Acetazolamide reduces exercise capacity and increases leg fatigue under hypoxic conditions. J. Appl. Physiol. 94: 991-996 [Abstract] [Full text]  
• Ellsworth, A. (2003). Pharmacotherapy for Altitude-Related Illness. Journal of Pharmacy Practice 16: 68-75 [Abstract]  
• Brundrett, G (2002). Sickness at high altitude: a literature review. The Journal of the Royal Society for the Promotion of Health 122: 14-20 [Abstract]  
• Basnyat, B., Ogilvie, R.I., White, A. P., O'Brien, B., Hackett, P. H., Roach, R. C. (2001). High-Altitude Illness. NEJM 345: 1279-1281 [Full text]  
• Hackett, P. H., Roach, R. C. (2001). High-Altitude Illness. NEJM 345: 107-114 [Full text]  
• Moore, K, Thompson, C, Hayes, R (2001). Diabetes and extreme altitude mountaineering. Br. J. Sports. Med. 35: 83-83 [Full text]  
• Hackett, P., Bartsch, P., Schneider, M., Dumont, L, Tramer, M R, Mardirosoff, C (2001). Pharmacological prevention of acute mountain sickness. BMJ 322: 48-48 [Full text]  
• Abell, L., Dumont, L., Mardirosoff, C., Tramer, M. R., Ryan, E. T., Kain, K. C. (2000). Health Advice for Travelers. NEJM 343: 1045-1046 [Full text]  

Rapid Responses:

Read all Rapid Responses

Systematic reviews win in the absence of guidelines

Martin Goldman
bmj.com, 21 Aug 2000 [Full text]

AMS prophylaxis review.

Simon Mitchell
bmj.com, 24 Aug 2000 [Full text]

Prophylaxis of acute mountain sickness - a few cautions

Ken Zafren
bmj.com, 17 Sep 2000 [Full text]

Acetazolamide dose and acute mountain sickness

John B West
bmj.com, 20 Sep 2000 [Full text]

Recommendation not justified

Peter Bärtsch
bmj.com, 25 Sep 2000 [Full text]

Diamox in the mountains of Nepal

Buddha Basnyat
bmj.com, 13 Oct 2000 [Full text]

Flawed analysis

Peter Hackett
bmj.com, 29 Sep 2000 [Full text]

Authors’ reply

Lionel Dumont, et al.
bmj.com, 1 Nov 2000 [Full text]